On Tuesday, Alector, Inc. (NASDAQ:ALEC) announced results from the Phase 3 INFRONT-3 trial evaluating latozinemab (AL001) for frontotemporal dementia caused by a progranulin gene mutation (FTD-GRN).ALEC stock is struggling to find support. Watch the momentum hereIn the 96-week study, latozinemab, developed in collaboration with GSK plc (NYSE:GSK), did not meet the clinical co-primary endpoint of slowing FTD-GRN progression, as measured by the Clinical Dementia Rating plus National Alzheimer's Coordinating C ...